ReviewCancers2023
Lipocalin-2: A Nurturer of Tumor Progression and a Novel Candidate for Targeted Cancer Therapy.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 24 citations in OpenAlex.
- Iron, inflammation, and intestinal tumors: the crucial triad in colorectal cancer progression and therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Palmitate promotes liver metastases by decreasing neutrophil antitumour behaviour.Nature metabolism · 2026Article
- Notch signaling regulates the secretion of pro-metastatic factors in extracellular vesicles in liposarcoma.Cancer letters · 2026Article
- Multi-scale evidence chain: Linking environmental BPA exposure to ovarian cancer through integrated omics and experimental models.Translational oncology · 2026Article
- Grade III canine and feline mammary carcinomas are associated with an immunosuppressed, vascularized and proliferative microenvironment.BMC veterinary research · 2026Article
- Emerging roles of lipocalin-2-mediated neuroimmune interactions in chronic pain and itch.Frontiers in pharmacology · 2026Review
- Serum NGAL and G-CSFR as Predictive and Prognostic Biomarkers for Trastuzumab-Based Therapy in HER2-Positive Gastric Cancer: A Retrospective Study.Cancer management and research · 2026Article
- Exploring the Association of Interleukin 13 Polymorphism (rs20541) and Serum Lipocalin 2 with Risk and Disability in Multiple Sclerosis.Journal of inflammation research · 2026Article
- Tumor-derived lactate fuels the STAT3-LCN2 pathway to promote bladder cancer malignancy and chemoresistance.Scientific reports · 2025Article
- HMGB1 orchestrates tumor-osteoclast crosstalk to drive bone metastasis in hepatocellular carcinoma.Cell death & disease · 2025Article
- Regulation of LCN-2/PI3K/Akt on TNF-α induced inflammatory response of porcine intramuscular adipocytes.In vitro cellular & developmental biology. Animal · 2025Article
- EGFRvIII-driven microenvironmental fibroblast activation and transformation accelerate oral cancer progression via lipocalin-2/STAT3 axis.Neoplasia (New York, N.Y.) · 2025Article
- Special status of iron transfer proteins in the serum of breast cancer patients.Discover oncology · 2025Article
- Article
- Sex- and site-specific associations of circulating lipocalin 2 and incident colorectal cancer: Results from the EPIC cohort.International journal of cancer · 2025Article
- Decoding iron deficiency in cancer: mechanisms, immune modulation, and therapeutic potential.Frontiers in nutrition · 2025Review
- Mechanisms of tumor-associated macrophages in breast cancer and treatment strategy.Frontiers in immunology · 2025Review
- Identification of Shared Diagnostic Biomarkers LCN2 and DUOX2 for Inflammatory Bowel Disease and Cholangiocarcinoma Through Integrative Bioinformatics and Machine Learning.Journal of inflammation research · 2025Article
- Lipocalin-2 and intestinal diseases.World journal of gastroenterology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Within the tumor microenvironment (TME) exists a complex signaling network between cancer cells and stromal cells, which determines the fate of tumor progression. Hence, interfering with this signaling network forms the basis for cancer therapy. Yet, many types of cancer, in particular, solid tumors, are refractory to the currently used treatments, so there is an urgent need for novel molecular targets that could improve current anti-cancer therapeutic strategies. Lipocalin-2 (Lcn-2), a secreted siderophore-binding glycoprotein that regulates iron homeostasis, is highly upregulated in various cancer types. Due to its pleiotropic role in the crosstalk between cancer cells and stromal cells, favoring tumor progression, it could be considered as a novel biomarker for prognostic and therapeutic purposes. However, the exact signaling route by which Lcn-2 promotes tumorigenesis remains unknown, and Lcn-2-targeting moieties are largely uninvestigated. This review will (i) provide an overview on the role of Lcn-2 in orchestrating the TME at the level of iron homeostasis, macrophage polarization, extracellular matrix remodeling, and cell migration and survival, and (ii) discuss the potential of Lcn-2 as a promising novel drug target that should be pursued in future translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.